论文部分内容阅读
目的 :探讨PCNA、c erbB 2与乳腺癌发生、发展的关系 ,及其在乳腺癌的临床分期、预后及治疗上的意义。方法 :采用免疫组化ABC法 ,对 52例乳腺癌患者术后病理组织进行检测。结果 :PCNA与临床分期、激素受体及腋淋巴结转移情况呈正相关 ,有淋巴结转移者较无淋巴结转移者阳性表达差异有显著性 (P <0 0 1) ;c erbB 2与临床分期呈正相关 ,与激素受体呈负相关。结论 :PCNA、c erbB 2作为联合指标对乳腺癌的分期、预后的判断有一定的意义 ,并对指导治疗 ,特别是内分泌治疗也起到辅助性作用。
Objective: To investigate the relationship between the expression of PCNA, c erbB 2 and the occurrence and development of breast cancer, and their significance in the clinical stage, prognosis and treatment of breast cancer. Methods: Immunohistochemical ABC method was used to detect pathological tissues in 52 cases of breast cancer patients. Results: There was a positive correlation between PCNA and clinical stage, hormone receptor and axillary lymph node metastasis, positive expression of PCNA in patients with lymph node metastasis and no lymph node metastasis (P <0.01), c erbB 2 was positively correlated with clinical stage, Negatively correlated with hormone receptor. CONCLUSION: PCNA and c erbB 2, as joint markers, have certain significance on the staging and prognosis of breast cancer, and also play an auxiliary role in guiding the treatment, especially the endocrine therapy.